Y Intercept Hong Kong Ltd Has $147,000 Stock Holdings in Zymeworks Inc. (NYSE:ZYME)

Y Intercept Hong Kong Ltd lessened its stake in Zymeworks Inc. (NYSE:ZYME - Free Report) by 79.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,724 shares of the company's stock after selling 46,586 shares during the period. Y Intercept Hong Kong Ltd's holdings in Zymeworks were worth $147,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in ZYME. Jane Street Group LLC increased its holdings in shares of Zymeworks by 27.3% in the 3rd quarter. Jane Street Group LLC now owns 80,326 shares of the company's stock valued at $1,008,000 after purchasing an additional 17,205 shares in the last quarter. State Street Corp grew its holdings in Zymeworks by 6.1% in the 3rd quarter. State Street Corp now owns 1,171,777 shares of the company's stock valued at $14,706,000 after buying an additional 67,401 shares during the period. Stifel Financial Corp grew its holdings in Zymeworks by 2.1% in the third quarter. Stifel Financial Corp now owns 73,654 shares of the company's stock valued at $924,000 after purchasing an additional 1,540 shares during the period. Vestal Point Capital LP raised its stake in Zymeworks by 39.8% during the third quarter. Vestal Point Capital LP now owns 615,000 shares of the company's stock worth $7,718,000 after purchasing an additional 175,000 shares during the period. Finally, FMR LLC grew its stake in shares of Zymeworks by 84.2% during the 3rd quarter. FMR LLC now owns 3,336 shares of the company's stock valued at $42,000 after buying an additional 1,525 shares during the period. Hedge funds and other institutional investors own 92.89% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on ZYME shares. Stifel Nicolaus boosted their price target on Zymeworks from $21.00 to $28.00 and gave the company a "buy" rating in a research report on Monday, October 28th. Leerink Partnrs raised shares of Zymeworks from a "hold" rating to a "strong-buy" rating in a research report on Thursday, November 7th. HC Wainwright reaffirmed a "neutral" rating and set a $12.00 price objective on shares of Zymeworks in a research report on Friday, November 22nd. Wells Fargo & Company raised their target price on Zymeworks from $12.00 to $14.00 and gave the company an "equal weight" rating in a research report on Thursday. Finally, JPMorgan Chase & Co. upgraded shares of Zymeworks from a "neutral" rating to an "overweight" rating and set a $18.00 price target on the stock in a research report on Monday. Two equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Zymeworks has a consensus rating of "Moderate Buy" and a consensus price target of $19.17.

Zymeworks Stock Performance

Shares of NYSE:ZYME traded up $0.56 on Friday, hitting $14.14. The stock had a trading volume of 1,608,115 shares, compared to its average volume of 613,146. Zymeworks Inc. has a twelve month low of $7.97 and a twelve month high of $17.70. The firm's 50 day moving average price is $14.17 and its 200-day moving average price is $11.81. The company has a market capitalization of $973.93 million, a price-to-earnings ratio of -9.43 and a beta of 1.12.

Zymeworks (NYSE:ZYME - Get Free Report) last issued its earnings results on Thursday, October 31st. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.01. The firm had revenue of $16.00 million during the quarter, compared to the consensus estimate of $17.90 million. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. The business's quarterly revenue was down 3.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.41) earnings per share. As a group, sell-side analysts predict that Zymeworks Inc. will post -1.43 EPS for the current year.

Zymeworks Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.